Experimental myocardial stem cell therapy for ST-elevation myocardial infarction: rationale and level of evidence

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Stem Cell Biology

Background:

• Ischemic heart disease (IHD), a major global cause of death, involves atherosclerotic plaque formation in coronary arteries, leading to reduced blood supply to the heart muscle.
• IHD can manifest as ST-elevation myocardial infarction (STEMI), chronic IHD, and heart failure, all characterized by the loss of functional cardiomyocytes and endothelial cells.
• Patients experience symptoms like chest pain (angina) and dyspnea, significantly reducing their quality of life.

Purpose of the Study:

• To review and clarify the current status of stem cell therapy for myocardial regeneration following ST-elevation myocardial infarction (STEMI).
• To explore the factors contributing to the diverse clinical outcomes observed in stem cell treatment for STEMI.

Main Methods:

• Review of preclinical and clinical studies on stem cell therapy in the context of STEMI.
• Analysis of various factors influencing stem cell treatment efficacy, including cell isolation, infarct location, delivery timing and route, cell dosage, and cell type.

Main Results:

• Numerous studies demonstrate encouraging results for stem cell therapy in preclinical and clinical settings post-STEMI.
• Significant variability in clinical outcomes has been reported, suggesting that treatment efficacy is highly dependent on multiple procedural and biological factors.
• Identified factors influencing outcomes include cell isolation techniques, infarct characteristics, delivery parameters, and cell type used.

Conclusions:

• Stem cell therapy represents a promising therapeutic strategy for myocardial regeneration after STEMI.
• The heterogeneity in clinical outcomes necessitates further research to standardize and optimize stem cell therapy protocols.
• Addressing factors such as cell source, delivery method, and timing is crucial for improving the efficacy of stem cell treatments for ischemic heart disease.